thebubbashow.org
Bristol-Myers Goes After Celgene
Bristol-Myers to Buy Celgene Bristol-Myers Squibb is making a $74 billion bet — and investors aren't pleased. The New York-based pharmaceutical giant on Thursday said it would acquire Celgene, a Summit, New Jersey-based cancer drug company, in a cash and stock deal valued at $74 billion. Under the agreement, Celgene shareholders will receive one Bristol-Myers Squibb